Diagnostic Pathology Course

Saturday, February 3, 2018 | 7:30 a.m. – 5:30 p.m. Add to Calendar

This live activity will update general surgical pathologists on the application of current classification systems of solid neoplasms and precursor lesions. These include molecular classification of bladder tumors, evaluation of circulating tumor cell in lung cancer, classification of neurofibromatosis, classification of gastrointestinal tumors especially pancreatic endocrine neoplasms and mucinous cystic lesions, gynecologic tumors as well as thyroid neoplasms. There are many new molecular and genetic approaches that can be used to classify solid neoplasms.

This activity will also inform the target audience of the significant problematic diagnostic issues and provide them with the information needed to avoid making diagnostic errors when confronted with these scenarios. Research on recently implemented diagnostic and prognostic molecular tests will be presented as well, so attendees can use this information to improve the accuracy of their clinical and histopathologic diagnoses and classification.

The activity content is expected to increase the attendees’ knowledge of the appropriate clinical use of diagnostic molecular testing, alter the attendees practice patterns to enable them to make more accurate diagnoses, and inform them of specific areas of diagnostic difficulty that will permit them to avoid diagnostic errors.

Educational Objectives
After attending the conference, participants should be able to:

  • Apply updated diagnostic criteria and new molecular tests for proper classification and treatment of neoplastic lesions (knowledge, competence, performance, patient outcomes)
  • Incorporate emerging and newly established biomarkers in classification of neoplasms and high risk lesions (knowledge, competence, performance, patient outcomes)
  • Practice appropriate use of molecular testing and tumor diagnosis (knowledge, competence, performance)

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

For more information and registration, visit: https://www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/diagnostic-pathology.html


The University of Texas MD Anderson Cancer Center

7455 Fannin St.
Houston, TX 77030


Eric Gagneaux